BIA Wants More Brexit Clarity From UK Regulator As Odds Narrow On ‘No-Deal’ Outcome
Executive Summary
The BioIndustry Association is concerned about the lack of clarity on future UK-EU drug regulation after EU heads of state failed to make any tangible progress on Brexit at their much heralded end-of-June summit.
You may also be interested in...
EMA To Contact Sponsors Of Over 100 Drugs At Risk Of Shortage Post Brexit
The European Medicines Agency’s survey on industry’s preparedness for Brexit has raised serious concerns about the continued supply of 108 drugs that have manufacturing operations based solely in the UK.
No EMA Membership For UK After Brexit, Says European Council
The European Council’s draft guidelines on the future UK-EU relationship say that the UK, as a third country outside the EU single market, will not be able to participate in any EU agencies after Brexit, dashing hopes expressed by the government that the UK could have “associate membership” of the EMA. However, the UK BioIndustry Association remains optimistic that some form of regulatory cooperation can be negotiated in the interests of all stakeholders.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.